Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen Files Osteoporosis Drug In US Ahead Of Rival Merck

Executive Summary

Amgen Inc. and partner UCB Group have filed their osteoporosis drug romosozumab, which is anticipated to drive sales of more than $700m worldwide by 2023, in the US for the treatment of postmenopausal women at risk of fractures.

Advertisement

Related Content

Venture Funding Deals
3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi
Shire Looks To Build Around Xiidra, Sanofi Faces Toujeo Challenge, Amgen Downplays Romosozumab Data
Merck Loses Chance For Primary Care Blockbuster With Odanacatib Failure
Will Radius Health's Abaloparatide Data Do The Trick In Osteoporosis?
Amgen Plugs Away On Repatha, With Hope For New Monthly Product
Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol
Positive Data For Amgen/UCB's Romosozumab In Men With Osteoporosis
Amgen/UCB Poised For Osteoporosis Drug Filing On Back Of Mixed PhIII

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC096959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel